Volume 189 - Issue 1
Commercialism, choice and consumer protection: regulation of complementary medicines in Australia
Author: Nigel A Pollard
Med J Aust 2008; 189 (1): 50-53. || doi: 10.5694/j.1326-5377.2008.tb01901.x
Published online: 7 July 2008
Published online: 7 July 2008
To the Editor: In the January issue of the Journal, Harvey et al raised some serious concerns about the listing system for complementary medicines.1 In particular, they suggest scrapping the listing system (AUST L) and requiring complementary medicine (CM) products to be evaluated by the Therapeutic Goods Administration (TGA) for efficacy.
Scrapping the system would be a significant setback for natural medicines, which have an important role to play in the health system. Such a move would be likely to remove products from the market, while the problem outlined by Harvey et al is more about the claims made for products rather than the products themselves. Certain CM products play a valuable role in many chronic diseases, in situations where existing synthetic products are often lacking. The regulatory system should encourage evidence-based CM products, and appropriate sanctions and enforcement should downgrade the claims made on products that don’t have a specific evidence base.
CMs, especially herbal medicines, are complex products with numerous biologically active components. This means that the evidence is specific to the product and cannot be extrapolated. This fact has two important consequences for practitioners and the health system as a whole:
the “generic” concept of synthetic pharmaceuticals (eg, interchangeability of paracetamol-containing products) is invalid for CM, meaning that a prescription for “St John’s wort” for example is not reliable, as St John’s wort is not one substance; and
meta-analyses and systematic reviews of a “substance” (eg, a herb, or glucosamine) are easily misinterpreted because the products made from that “substance” are so different, any conclusions drawn can only be applied to the particular products that have been trialled.2
While the health system fails to discriminate between products that have specific trial evidence and those that do not, practising evidence-based complementary medicine will remain difficult. Encouraging evidence-based use of CM products, including supporting specifically clinically proven products, will lead to further research and better integration of CM into our health system for the benefit of the Australian public.
Competing interests
I am the Managing Director of an Australian complementary medicine company, and own shares in that company. No company product names have been mentioned, and the letter is an industry view on an article which examines issues in relation to complementary medicine products promoted in Australia.
References
- Harvey KJ, Korczak VS, Marron LJ, Newgreen DB. Commercialism, choice and consumer protection: regulation of complementary medicines in Australia. Med J Aust 2008; 188: 21-25.
- Linde K, Mulrow CD, Berner M, Egger M. St John’s wort for depression. Cochrane Database Syst Rev 2005; (2): CD000448. 0_i1091825
Country revealing the way: evaluating Elder‐governed cultural therapy for Aboriginal and Torres Strait Islander young people with mental health conditions
Alasdair Vance, Janet McGaw, Jo Winther, Naomi Tootell, Herb Patten, Sandra Eades
No silver lining with health misinformation: argyria caused by intentional silver consumption
Luke Collins, Logesh Palanikumar, Stephen Bacchi
Hyperkalaemic cardiac arrest due to cream of tartar ingestion
Daniel Yee Lee Ng, Laksmi Govindasamy, Andrew Hughes, Hwee Min Lee
From talk to action: Indigenous Reference Groups drive practice change in kidney transplantation care
Kelli J Owen, Katie Cundale, Jaquelyne T Hughes, Stephen P McDonald, Matilda D'Antoine, Shilpanjali Jesudason
The not‐so‐natural herb: a case of exogenous Cushing syndrome
Yi‐An Pan, David Roberts, Yi‐An Pan, David Roberts
Lead poisoning outbreak from consumption of contaminated Ayurvedic medication
Mark J Ferson, Sinead Flanigan, Toni Cains